While Zepbound alone showed significant efficacy, patients combining it with PAP therapy ... your policies. Lilly Investors encourages patients to consult with their health care providers and ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

You could pay about $171 per month for Mounjaro if you use a discount from the drug maker, Lilly, on top of insurance benefits ... can't get free Mounjaro through the drug maker's patient assistance ...

The Food and Drug Administration (FDA) on Dec. 20 approved the obesity medication Zepbound (tirzepatide) as the first pharmaceutical treatment for moderate-to-severe obstructive sleep apnea (OSA) in ...

But for these dermatologic toxicities, patients often have to do these various things for skin care multiple times ... whether or not a patient assistance program is going to have enough funding ...

Medicare beneficiaries with common chronic health conditions who complied with PAP therapy saw reduced costs, according to a new study.

While this is all great news for Verzenio, Lilly isn't stopping its ambitions in oncology care with just one treatment. Right now, the company has seven clinical trials underway exploring new ...

Health-care companies slid after a profit warning from Eli Lilly. Shares of the obesity-drug maker tumbled after it slashed its projection for fourth-quarter revenue as the market for drugs that ...

Northwell Health partnered with Stacker to explore how a new Pap smear alternative may help prevent deaths from cervical ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

In the new filing, Lilly says it wants to wade into the legal proceedings to “protect its interests and help bring this suit to a swift end.” The company’s lawyers further contend that OFA ...